|
|
|
|
| LEADER |
03363nam a2200349 u 4500 |
| 001 |
EB001999950 |
| 003 |
EBX01000000000000001162851 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Certolizumab pegol (Cimzia)
|h Elektronische Ressource
|b (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for Certolizumab pegol (Cimzia)
|
| 246 |
3 |
1 |
|a CDR Pharmacoeconomic review report for Cimzia
|
| 250 |
|
|
|a Version: Final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, January 2020
|
| 300 |
|
|
|a 1 PDF file (34 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Adult
|
| 653 |
|
|
|a Certolizumab Pegol / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Certolizumab Pegol / economics
|
| 653 |
|
|
|a Immunosuppressive Agents / therapeutic use
|
| 653 |
|
|
|a Psoriasis / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK565097
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Certolizumab pegol is a recombinant, humanized antibody Fab' fragment with specificity for human tumour necrosis factor alpha that is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol is available as a solution for subcutaneous injection in a single-use, pre-filled syringe or single-use pre-filled autoinjector containing 200 mg/mL of certolizumab pegol. The recommended dose is 400 mg administered via subcutaneous injection every two weeks. A dose of 400 mg at week 0 and week 4 followed by 200 mg every two weeks thereafter may be considered. At the manufacturer's submitted price of $664.51 per pre-filled syringe or autoinjector, and at the recommended dose of 400 mg every two weeks, the annual cost of certolizumab pegol is $34,555, whereas, at a 200 mg dose, the annual cost during the first year is $19,271 and $17,277 thereafter. The manufacturer submitted a cost-utility analysis based on a Markov state-transition model comparing certolizumab pegol with best supportive care (BSC) and the following biologic therapies reimbursed in Canada for moderate-to-severe plaque psoriasis: adalimumab, brodalumab, etanercept, guselkumab, infliximab (branded), ixekizumab, secukinumab, and ustekinumab. BSC consisted of treatment with cyclosporine, methotrexate, acitretin, and/or phototherapy. The analysis was conducted from a Canadian publicly funded health care payer perspective using two-week cycles over a lifetime horizon (defined as the period over which more than 99% of the modelled cohort is predicted to have died). An annual discount rate of 1.5% was applied to both costs and benefits. The model had two time periods: the initial period, from treatment initiation to the initial assessment of treatment response (i.e., 10 to 16 weeks), and the maintenance period
|